Furosemide 500mg tablets

Ülke: Birleşik Krallık

Dil: İngilizce

Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)

Aktif bileşen:

Furosemide

Mevcut itibaren:

Ennogen Healthcare Ltd

ATC kodu:

C03CA01

INN (International Adı):

Furosemide

Doz:

500mg

Farmasötik formu:

Oral tablet

Uygulama yolu:

Oral

Sınıf:

No Controlled Drug Status

Reçete türü:

Valid as a prescribable product

Ürün özeti:

BNF: 02020200

Bilgilendirme broşürü

Artwork No.
Customer
Description
Market
Language
Size
Min. Font Size
Page No.
Version No.
Date
Software
200917/1
Ennogen
Diuresal 500mg Leaflet
UK
English
160 x 500 mm
9 pt
1 of 1
4
08-02-17
Coreldraw 12
Packaging Development
Quality Assurance (QA)
Quality Control (QC)
Production
e-mail : [e-mail]
Ph : [phone]
Colours Used
Black
Keyline
DIURESAL 500MG TABLETS
[FUROSEMIDE]
PACKAGE LEAFLET: INFORMATION FOR THE USER
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START
TAKING THIS MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Keep this leaflet. You may need to read it
again.
If you have further questions, ask your doctor
or pharmacist or nurse.
This medicine has been prescribed for you
only. Do not pass it on to others. It may harm
them, even if their signs of illness are the same
as yours.
If you get any side effects, talk to your doctor,
pharmacist or nurse. This includes any possible
side effects not listed in this leaflet. See section
4.
WHAT IS IN THIS LEAFLET:
1.
WHAT DIURESAL TABLETS ARE AND WHAT THEY ARE
USED FOR
2.
WHAT YOU NEED TO KNOW BEFORE YOU TAKE
DIURESAL TABLETS
3.
HOW TO TAKE DIURESAL TABLETS
4.
POSSIBLE SIDE EFFECTS
5.
HOW TO STORE DIURESAL TABLETS
6.
CONTENTS OF THE PACK AND OTHER INFORMATION
Diuresal Tablets are one of a group of medicines
called diuretics (water tablets).
They are used to treat the abnormally low
production of urine caused by kidney disorders.
DO NOT TAKE DIURESAL TABLETS IF YOU:
Are allergic to furosemide or any of the other
ingredients of this medicine (listed in section 6).
Signs of an allergic reaction include: a rash,
swallowing or breathing problems, swelling of
the lips, face, throat or tongue
Are allergic to amiloride, sulfonamides or
sulphonamide derivatives, such as sulfadiazine
or cotrimoxazole
Have a low blood volume or are dehydrated
(with or without accompanying low blood
pressure)
Have too little potassium or sodium in your
blood (shown in blood test)
Have severe liver problems (cirrhosis)
Have already taken furosemide in the past to

Ürün özellikleri

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Furosemide 500mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Furosemide BP 500 mg.
Excipient(s) with known effect: Lactose, Ultralake tartrazine E102
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Tablet.
Yellow coloured round, flat uncoated tablets embossed with FW & 151 on
one
side of the tablets and a crossline on the other side of the tablets.
The score line is only to facilitate breaking for ease of swallowing
and not to
divide into equal doses.
4.
CLINICAL PARTICULARS
4.1.
THERAPEUTIC INDICATIONS
The management of oliguria due to acute or chronic renal failure.
_4.2 _
_POSOLOGY AND METHOD OF ADMINISTRATION _
Posology:
In patients with chronic renal insufficiency an initial daily dose of
250mg is
employed. If a satisfactory diuresis is not produced then the dose may
be increased in
steps of 250mg at 4 - 6 hourly intervals up to a maximum daily dose of
1,500mg in 24
hours. In exceptional cases up to 2,000mg in 24 hours may be given.
Method of administration:
For oral administration.
_ _
4.3
CONTRAINDICATIONS
- Hypersensitivity to furosemide or to any of the excipients listed in
section
6.1
-Hypersensitivity to amiloride, sulphonamides or sulphonamide
derivatives.
- Hypovolaemia and dehydration (with or without accompanying
hypotension)
(see section 4.4)
- Severe hypokalaemia: severe hyponatraemia (see section 4.4).
- Comatose or pre-comatose states associated with hepatic cirrhosis
(see
section 4.4).
- Anuria or renal failure with anuria not responding to furosemide,
renal
failure as a result of poisoning by nephrotoxic or hepatotoxic agents
or renal
failure associated with hepatic coma
- Impaired renal function with a creatinine clearance below 30ml/min
per 1.73
m
2
body surface area (see section 4.4).
- Addison's disease (see section 4.4).
- Children and adolescents under 18 years of age (safety in this age
group has
not yet been established).
- Digitalis intoxication (see section 4.5).
- Concomitant potassium